Pressreleases

Monowave 300 Goes Automation

A strategy for efficiency.

A Kilo a Day – Microwave Goes Kilolab

The all-new Masterwave BTR benchtop reactor for the first time transfers microwave synthesis to the kilolab. A revolutionary technique allows for efficient microwave heating of a 1L vessel.

Monowave 300 – A New Dimension of Microwave Synthesis

With the new Monowave 300 microwave synthesis reactor, Anton Paar enters the prosperous market of compact monomode microwave synthesisers. The smart and powerful instrument is designed to fully meet the needs and requirements of synthesis chemists in pharmaceutical and academic research departments.

CoreLab Partners Completes First TQT Study in Japan

CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm and Medifacts International in February of this year, has recently completed the first ever regulatory mandated Thorough QT (TQT) study conducted in the Asia Pacific Rim and the first TQT study for a Japanese new drug application (NDA).

GE Healthcare Launches Human Cardiomyocytes for Predictive Toxicity Testing

Enabling improved accuracy in drug safety through better toxicology testing.

Somerset House Consultants Assists US Contract Manufacturer with GMP Recertification

Somerset House Consultants has recently completed a major project for a US-based contract manufacturer. The company is an established manufacturer of both clinical trial supplies and marketed products for the US market, with a successful FDA inspection record. However, an inspection by European regulatory authorities had found that the company did not comply with EU GMP requirements and could not supply products to Europe.

Anaxsys Receives CE Mark for their Respiratory Rate Monitor with the Support of Exploristics

Exploristics, the innovative analysis group, is pleased to announce that Anaxsys Limited have received the CE Mark for their respiratory rate monitor, respiR8, from the British Standards Institute (BSI).

NMRPredict Version 4.8 Released

Version 4.8 of NMRPredict has been released, including many new features.

ARTES Steps Further Into the Vaccine Business by Acquiring Anavax

ARTES Biotechnology announced today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases.